Pepgen to focus on development of promising dm1 program following 10 mg/kg pgn-edo51 update

Boston--(business wire)--pepgen inc. (nasdaq: pepg), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies, today announced that based on the levels of dystrophin protein measured in the 10 mg/kg cohort of its connect1-edo51 study investigating pgn-edo51 in duchenne muscular dystrophy (dmd) patients amenable to exon 51 skipping, the company will focus on advancing its promising myotonic dystrophy type 1 (dm1) program currently in phase 2 clinical deve.
PEPG Ratings Summary
PEPG Quant Ranking